{"nctId":"NCT01310400","briefTitle":"Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children","startDateStruct":{"date":"2009-10"},"conditions":["Influenza"],"count":1356,"armGroups":[{"label":"Inflexal 0.5 mL","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V"]},{"label":"Inflexal 0.25 mL","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V"]},{"label":"Agrippal 0.25 mL","type":"EXPERIMENTAL","interventionNames":["Biological: Agrippal"]}],"interventions":[{"name":"Inflexal V","otherNames":[]},{"name":"Inflexal V","otherNames":[]},{"name":"Agrippal","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥6months to ≤35 months-old healthy children (male or female) born at term after normal pregnancy\n* Recording of medical history and physical examination reveal no abnormality\n* The parent/legal guardian of the participating child must sign the written informed consent and agree to provide a blood sample taken from the child pre- and post-immunization\n\nExclusion criteria:\n\n* Hypersensitivity to eggs, chicken proteins, polymyxin B, neomycin or any component of the vaccine\n* Previous vaccination against influenza\n* At time of enrollment, presentation of clinical symptoms of active infection and/or body temperature ≥38°C\n* Confirmation or suspicion of immunosuppressed status (including cancer), or confirmation of immunodeficiency disease (congenital or acquired including HIV)\n* Medical treatment (\\>2 weeks) with immune suppressant or immune modulating drugs including systemic steroids during the last 3 months before immunization or at present, as follows: long-term oral prednisone or other equivalent steroid: ≥0.5mg/kg/day (note: administration of local or inhaled steroids before or during the study is allowed)\n* Treatment with immunoglobulins or blood products during the last 3 months before immunization or such treatment scheduled during the study\n* Participation in other clinical trials during the last 3 months before immunization or intention to participate during this study period\n* At present or during the last 6 months before immunization: radiotherapy or treatment with cytotoxic drugs\n* Other vaccination with a killed vaccine within 14 days before immunization or with an attenuated vaccine within 28 days before immunization (note: after subject inclusion vaccines of the immunization program for children are allowed upon the physician's discretion. However, immunization on the same day must be avoided)\n* Family history of Guillain-Barré Syndrome\n* Severe congenital deficiency or disease\n* Antecedent of neurological disease or epileptic attack\n* Severe cardiopulmonary disease with possibility to influence the study result\n* Disturbance of coagulation or under anticoagulant treatment, likely to be contraindicated to i.m. injection\n* Suspected non-compliance","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"35 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity, Assessed by the Haemagglutination (HI) Test","description":"Seroconversion rate post-immunization. Seroconversion is defined as a post-vaccination titer of ≥1:40 for those with a pre-vaccination HI titer of \\<1:10 and as ≥ four-fold increase in HI titer for those with a pre-vaccination HI titer of ≥1:10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null},{"groupId":"OG001","value":"89.7","spread":null},{"groupId":"OG002","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null},{"groupId":"OG001","value":"83.4","spread":null},{"groupId":"OG002","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":null},{"groupId":"OG001","value":"47.9","spread":null},{"groupId":"OG002","value":"37.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Fold Increase in Geometric Mean Titer (GMT)","description":"GMT-fold increase - calculated as the GMT on Day 49 divided by the baseline GMT value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":null},{"groupId":"OG001","value":"25.9","spread":null},{"groupId":"OG002","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"48.8","spread":null},{"groupId":"OG002","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"7.0","spread":null},{"groupId":"OG002","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroprotection","description":"Seroprotection rate, defined as a post-vaccination HI titer of 1:40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"92.1","spread":null},{"groupId":"OG002","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"84.5","spread":null},{"groupId":"OG002","value":"82.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null},{"groupId":"OG001","value":"51.3","spread":null},{"groupId":"OG002","value":"39.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety: Incidence of Solicited and Unsolicited Adverse Events","description":"Safety assessements were made by the investigator at baseline and on Days 28 and 49, as well as by the subjects themselves (in Subjects Diaries) for the 4-day period following each vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"33.0","spread":null},{"groupId":"OG002","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":null},{"groupId":"OG001","value":"29.1","spread":null},{"groupId":"OG002","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"8.2","spread":null},{"groupId":"OG002","value":"12.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":452},"commonTop":["Pyrexia (body temp. >=38°C)","Cough","Rhinorrhea","Vomiting","Diarrhea"]}}}